![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Michigan Researchers to Begin Trial of Combination Therapy for COVID-19
Michigan Researchers to Begin Trial of Combination Therapy for COVID-19
![COVID-19 Treatment](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-treatment.gif?t=1585949056&width=430)
Researchers at Beaumont Hospital in Royal Oak, Mich., are enrolling patients in a phase 2 trial to evaluate a combination of naltrexone and ketamine as a treatment for COVID-19.
Low-dose naltrexone is used to treat pain and inflammation in multiple sclerosis, Crohn’s disease, fibromyalgia and other pain conditions. Ketamine, an anesthetic, shows anti-inflammatory effects when taken early in the inflammatory process.
The study aims to see if the combination can lessen the severity of COVID-19 symptoms by reducing inflammation.
Upcoming Events
-
18Jul
-
21Oct